ImmunoCellular Therapeutics, Ltd.
(NYSE Amex Equities : IMUC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
1.43%73.640.9%$618.50m
CELGCelgene Corporation
1.91%129.861.1%$445.98m
AMGNAmgen Inc.
1.30%170.341.1%$413.39m
BIIBBiogen Inc.
1.26%286.711.2%$361.14m
REGNRegeneron Pharmaceuticals, Inc.
2.26%480.352.7%$325.98m
VRTXVertex Pharmaceuticals Incorporated
3.34%153.991.9%$237.44m
ALXNAlexion Pharmaceuticals, Inc.
3.17%137.651.9%$221.39m
ILMNIllumina, Inc.
1.48%193.513.5%$217.92m
INCYIncyte Corporation
0.98%122.082.6%$133.06m
CLVSClovis Oncology, Inc.
-0.87%70.5818.0%$128.07m
KITEKite Pharma, Inc.
1.63%136.0916.1%$126.91m
TSROTESARO, Inc.
-0.43%118.3514.7%$123.56m
AAgilent Technologies, Inc.
1.43%62.621.5%$122.20m
BMRNBioMarin Pharmaceutical Inc.
0.88%81.314.4%$106.89m
SRPTSarepta Therapeutics, Inc.
0.76%36.0019.8%$98.17m

Company Profile

ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. Its lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 31, 2006 and is headquartered in Calabasas, CA.